Wallace R J, Brown B A, Silcox V A, Tsukamura M, Nash D R, Steele L C, Steingrube V A, Smith J, Sumter G, Zhang Y S
Department of Microbiology, University of Texas Health Center, Tyler 75710.
J Infect Dis. 1991 Mar;163(3):598-603. doi: 10.1093/infdis/163.3.598.
Previous studies of Mycobacterium fortuitum identified isolates that did not fit its two recognized biovariants. Eighty-five clinical isolates of this group, the "third biovariant complex", were evaluated. They represented 16% of 410 isolates of M. fortuitum submitted to a Texas laboratory and 22% of 45 isolates in Queensland, Australia. Most infections (76%) involved skin, soft tissue, or bone and occurred after metal puncture wounds or open fractures. Isolates differed from biovar fortuitum in resistance to pipemidic acid and use of mannitol and inositol as carbon sources. Two subgroups were present, and examples were deposited in the American Type Culture Collection. Isolates were resistant to doxycycline and one-third were resistant to cefoxitin. All were susceptible to amikacin, ciprofloxacin, sulfamethoxazole, and imipenem. Surgical debridement combined with drug therapy based on in vitro susceptibilities resulted in cures of cutaneous disease or osteomyelitis. DNA homology studies are needed to determine the taxonomic status of these organisms.
先前对偶然分枝杆菌的研究发现了一些不符合其两个公认生物变种的菌株。对该组的85株临床分离株（“第三生物变种复合体”）进行了评估。它们占提交给德克萨斯州一家实验室的410株偶然分枝杆菌分离株的16%，以及澳大利亚昆士兰州45株分离株的22%。大多数感染（76%）累及皮肤、软组织或骨骼，发生在金属刺伤或开放性骨折之后。这些分离株在对吡哌酸的耐药性以及将甘露醇和肌醇用作碳源方面与偶然生物变种不同。存在两个亚组，并将实例保藏于美国典型培养物保藏中心。分离株对强力霉素耐药，三分之一对头孢西丁耐药。所有分离株均对阿米卡星、环丙沙星、磺胺甲恶唑和亚胺培南敏感。手术清创结合基于体外药敏试验的药物治疗可治愈皮肤疾病或骨髓炎。需要进行DNA同源性研究以确定这些微生物的分类地位。
